Why I’m thinking of AstraZeneca as a great long-term buy

Motley Fool contributor Jay Yao writes why he’s looking at FTSE 100 component AstraZeneca as a great long-term investment.

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in.

Read More

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk. Currency exchange rates are constantly changing, which may affect the value of the investment in sterling terms. You could lose money in sterling even if the stock price rises in the currency of origin. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, and may have other tax implications, and may not provide the same, or any, regulatory protection as in the UK.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

Although there’s a lot of quality in the FTSE 100, I think one of the best FTSE stocks to hold for the long term is AstraZeneca (LSE: AZN)

Numerous FTSE 100 companies are profitable with substantial competitive advantages. Many stocks in the leading index are also trading lower than their levels last year. But, in my view, few of them have AstraZeneca’s combination of quality and exposure to long-term trends and technology advancements. 

In terms of exposure to long-term trends, one of the most encouraging is AZN’s emerging markets business. Here’s more on the pharma giant’s rapidly growing division:

Fast growing emerging markets business

AstraZeneca has substantial exposure to emerging markets. For fiscal year 2019, 35% of the company’s total sales came from emerging markets. The pharma giant’s business in those markets grew 24% year-on-year at constant exchange rates to $8.16bn. In China, AstraZeneca’s business grew even faster, with sales rising 35% year-on-year at constant exchange rates to $4.48 bn. 

And there could be a lot more room for growth in emerging markets in the future. China’s economy could potentially outpace the US economy in the next decade. However, China’s pharmaceutical market only accounts for 8% of global sales, versus 48% for the US. 

One of the fastest growing big pharma companies in emerging markets

In terms of its big pharma peers, AstraZeneca is in a pretty good position, in my view. It was the fastest-growing top-10 multinational pharmaceutical corporation in emerging markets last year. In terms of 2019 prescription sales in emerging markets, the company was also the fourth-largest multinational. 

I think AstraZeneca’s status as one of the leaders in emerging markets among big pharma companies is good for the stock because it could ultimately give AZN a higher valuation. 

If the market prioritises emerging markets more as global economic growth returns, I believe AZN would be one of the first stocks that many investors would consider. That extra demand could translate into higher share prices. 

Going forward, I also think AstraZeneca’s total growth rate could potentially beat expectations. The company’s emerging markets business is growing rapidly and the segment will very likely account for a bigger percentage of total sales. While AstraZeneca’s emerging market sales grew 24% in constant currency last year, the company’s total sales only grew 13% in constant currency.

Covid-19 vaccine potential

In addition to its emerging markets potential, AstraZeneca has a promising Covid-19 vaccine candidate. Just recently, the company disclosed that its vaccine candidate produced similar immune responses in younger and older adults. Even better in my view, the adverse responses to the vaccine candidate among the elderly were lower. 

Given the elderly response data, I think there is potential for more upside if the vaccine is approved given the potential for a larger target market.

Foolish conclusion

AstraZeneca’s emerging markets business is growing quickly and has a lot of potential given the market’s huge populations, rising incomes, and unmet needs. 

In terms of AZN stock, I think it has substantial upside despite the fact that it hasn’t changed very much year-to-date. 

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

Jay Yao has no position in any of the shares mentioned. The Motley Fool UK has no position in any of the shares mentioned. Views expressed on the companies mentioned in this article are those of the writer and therefore may differ from the official recommendations we make in our subscription services such as Share Advisor, Hidden Winners and Pro. Here at The Motley Fool we believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Investing Articles

Could the JD Sports Fashion share price double in the next five years?

The JD Sports Fashion share price has nearly halved in the past five years. Our writer thinks a proven business…

Read more »

Bus waiting in front of the London Stock Exchange on a sunny day.
Investing Articles

If interest rate cuts are coming, I think these UK growth stocks could soar!

Falling interest could be great news for UK growth stocks, especially those that have been under the cosh recently. Paul…

Read more »

Investing Articles

Are these the best stocks to buy on the FTSE right now?

With the UK stock market on the way to hitting new highs, this Fool is considering which are the best…

Read more »

Petrochemical engineer working at night with digital tablet inside oil and gas refinery plant
Investing Articles

Can the Centrica dividend keep on growing?

Christopher Ruane considers some positive factors that might see continued growth in the Centrica dividend -- as well as some…

Read more »

Smiling family of four enjoying breakfast at sunrise while camping
Investing Articles

How I’d turn my £12,000 of savings into passive income of £1,275 a month

This Fool is considering a strategy that he believes can help him achieve a stable passive income stream with a…

Read more »

Person holding magnifying glass over important document, reading the small print
Investing Articles

2 top FTSE 250 investment trusts trading at attractive discounts!

This pair of discounted FTSE 250 trusts appear to be on sale right now. Here's why I'd scoop up their…

Read more »

Smiling young man sitting in cafe and checking messages, with his laptop in front of him.
Investing Articles

3 things that could push the Lloyds share price to 60p and beyond

The Lloyds share price has broken through 50p. Next step 60p? And then what? Here are some thoughts on what…

Read more »

Young female business analyst looking at a graph chart while working from home
Investing Articles

£1,000 in Rolls-Royce shares a year ago would be worth this much now

Rolls-Royce shares have posted one of the best stock market gains of the past 12 months. But what might the…

Read more »